SFDA and KFSHRC Sign Agreement to Enhance Pharmaceutical Product Safety

The Saudi Food and Drug Authority (SFDA) has signed a cooperation agreement with the King Faisal Specialist Hospital and Research Centre (KFSHRC) to enhance the national safety database owned by the SFDA. The goal is to support safety research related to pharmaceutical products, contributing to regulatory decisions based on scientific evidence that improve community health and safety.

The agreement was signed on the sidelines of the Global Health Exhibition 2024 in Riyadh, which will be held from October 21 to 23, by the Chief Executive Officer of the SFDA, H.E. Dr. Hisham S. Aljadhey, and the Chief Executive Officer of KFSHRC, H.E. Dr. Majid I. Al-Fayyad.

The agreement aims to contribute to the National Safety Database by providing necessary data to support research on the safety of pharmaceutical products. This, in turn, will contribute to regulatory decisions based on scientific evidence that help improve public health and safety.

The agreement will enhance research on the safety of pharmaceutical products, improve the quality of healthcare, reduce potential risks, develop modern safety standards that address emerging health challenges, and maximize the use of medical data in scientific research and studies that directly benefit individual and public health and safety.